A new bill would make drug pricing more fair for Californians | Opinion - Insurance News | InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home Now reading Newswires
Topics
    • Advisor News
    • Annuity Index
    • Annuity News
    • Companies
    • Earnings
    • Fiduciary
    • From the Field: Expert Insights
    • Health/Employee Benefits
    • Insurance & Financial Fraud
    • INN Magazine
    • Insiders Only
    • Life Insurance News
    • Newswires
    • Property and Casualty
    • Regulation News
    • Sponsored Articles
    • Washington Wire
    • Videos
    • ———
    • About
    • Meet our Editorial Staff
    • Advertise
    • Contact
    • Newsletters
  • Exclusives
  • NewsWires
  • Magazine
  • Newsletters
Sign in or register to be an INNsider.
  • AdvisorNews
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Exclusives
  • INN Magazine
  • Insurtech
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Video
  • Washington Wire
  • Life Insurance
  • Annuities
  • Advisor
  • Health/Benefits
  • Property & Casualty
  • Insurtech
  • About
  • Advertise
  • Contact
  • Editorial Staff

Get Social

  • Facebook
  • X
  • LinkedIn
Health/Employee Benefits News
Newswires RSS Get our newsletter
Order Prints
October 6, 2025 Newswires
Share
Share
Post
Email

A new bill would make drug pricing more fair for Californians | Opinion

Paul Markovich, The Sacramento BeeSacramento Bee

It’s time to stop kickbacks on prescription drugs

As the president and CEO of Ascendiun, the nonprofit parent company of Blue Shield of California — one of California’s largest health insurers — I believe that all health care decision-making should be based on what is best for the patient. Yet, in the murky world of pharmacy benefit managers and drug pricing, kickbacks (such as fees, rebates and incentives for prescribing one drug over another) distort the market.

That’s why we need Senate Bill 41, authored by Sen. Scott Wiener, D-San Francisco, which will require a more fair and transparent pricing model for pharmacy benefit managers, the third-party companies that manage prescription drug benefits on behalf of health insurers, employers, unions and government programs. Pharmacy benefit managers often accept a kickback from drug manufacturers in exchange for placement of a particular (and usually more expensive) drug on the list of covered medications, also known as a formulary.

SB 41 makes three important changes: First, pharmacy benefit managers must ensure that all rebates go to the payer and consumers; it de-links the fees they charge from the cost of the drug, eliminating the incentive to place higher cost drugs on formularies; and third, it eliminates their ability to mark-up generics. These reforms will put consumers’ interests first and go a long way toward fulfilling Blue Shield of California’s non-profit mission of creating a health care system that is affordable for all.

SB 41 is common sense and bipartisan. Democrats and Republicans across the country and in the halls of Congress all agree that pharmacy benefit managers need to be reigned in. So does President Donald Trump, who declared: “We’re going to cut out the middleman and facilitate the direct sale of drugs at the most favored national price directly to the American citizen.”

Naturally, there is opposition to this bill largely from those who financially benefit from the current way of doing business. Granted, they would never say their advocacy is a result of financial self-interest, but we all know better.

Here’s why these kickbacks are so problematic: Consider the case of Humira, a drug used to treat a variety of inflammatory conditions such as rheumatoid arthritis. With the patent expiration, numerous other companies began to offer the same kind of drug in a generic form, referred to as “biosimilars.” One of those companies, Fresenius Kabi, agreed to sell a Humira biosimilar to Blue Shield of California for $545 per monthly dose as compared to the nearly $7,000 monthly “list price” and the approximately $2,100 net price with “rebates and fees” for Humira.

With competition like that, why would anyone buy Humira? But people did. In January of 2024, one year after biosimilars became available, Humira had a 96% market share, and the drug maintained more than 70% market share for all of 2024. With such highly credible alternatives available for a fraction of the price for such a long time, how is this possible? It has to do with the kickbacks.

The “business model” for pharmacy benefit managers is to negotiate rebates from drug manufacturers that are tied to the list price of the drug and formulary placement fees based upon the list price of the drug. In the case of Humira, last year there were nearly $5,000 of rebates and fees kicked back to pharmacy benefit managers each month for each patient. While a lot of that money was then passed back to others, including health plans and employers, much of that money was skimmed off the top by pharmacy benefit managers and their affiliates.

All of this is legal, but it shouldn’t be. By enacting SB 41, we can foster a more fair, equitable health care system.

Paul Markovich is president and CEO of Ascendiun (formerly president and CEO of Blue Shield of California).

©2025 The Sacramento Bee. Visit sacbee.com. Distributed by Tribune Content Agency, LLC.

Older

Financial Services Committee Republicans raise concerns about missing former SEC chairman text messages

Newer

Fed Minutes, Powell’s Speech, and Jobless Data Eye Crypto Impact

Advisor News

  • Semi-retirement: helping clients balance flexibility with financial security
  • The 6X Formula for leveraging content marketing with AI
  • When a home becomes difficult to insure, the plan changes
  • The inheritance gap: Helping clients plan for money that hasn’t arrived
  • After the midterms: Addressing your clients’ tax concerns
More Advisor News

Annuity News

  • Athene CEO criticizes offshore reinsurance, risk-taking by competitors
  • DOL, trade groups, state AGs file briefs supporting Alcoa in PRT lawsuit
  • John Hancock launches new fixed indexed annuity suite
  • Annuities to play a larger role in workplace retirement plans
  • FHLBank Pittsburgh Announces Results in 2026 Board Election
More Annuity News

Health/Employee Benefits News

  • Patients with 3 health insurance plans lose access to Miami health network
  • Weld County deputy struggling after being injured by DUI driver (photo gallery)
  • Changes to Medicare Advantage plan offerings affect Montana seniors
  • Medicaid work rules don’t apply to Native Americans. They could still lose coverage.
  • Native Americans face Medicaid exemption hurdles
More Health/Employee Benefits News

Life Insurance News

  • Best’s Market Segment Report: AM Best Maintains Stable Outlook on New Zealand’s Non-Life Insurance Segment
  • AM Best Affirms Credit Ratings of Fubon Insurance Vietnam Co., Ltd.
  • Three lawsuits put life insurers’ cost-of-insurance practices under scrutiny
  • Military Briefs: November 12-18
  • Security Benefit Series B Preferred Stock Dividend Rate Resets to 10.286%
More Life Insurance News

NEWS INSIDE

  • Companies
  • Earnings
  • Economic News
  • INN Magazine
  • Insurtech News
  • Newswires Feed
  • Regulation News
  • Washington Wire
  • Videos

FEATURED OFFERS

Press Releases

  • Insurvoice Lets Independent Insurance Agency Owners Analyze Every Customer Call in ChatGPT or Claude
  • Spectrum Weather & Specialty Insurance Celebrates 15 Years and Welcomes the Next Generation
  • Royal Neighbors of America® Increases Service Capacity
  • Benefits Studio Launches to Fill the Missing Middle of Benefits Navigation at $49/mo
  • Lauren Sinnott Named to Ragan’s Top Women in Marketing Awards, Class of 2026 
More Press Releases > Add Your Press Release >

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

Topics

  • Advisor News
  • Annuity Index
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • From the Field: Expert Insights
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Magazine
  • Insiders Only
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Washington Wire
  • Videos
  • ———
  • About
  • Meet our Editorial Staff
  • Advertise
  • Contact
  • Newsletters

Top Sections

  • AdvisorNews
  • Annuity News
  • Health/Employee Benefits News
  • InsuranceNewsNet Magazine
  • Life Insurance News
  • Property and Casualty News
  • Washington Wire

Our Company

  • About
  • Advertise
  • Contact
  • Meet our Editorial Staff
  • Magazine Subscription
  • Write for INN

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2026 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • InsuranceNewsNet Magazine

Sign in with your Insider Pro Account

Not registered? Become an Insider Pro.